Dr. Sharman on the Phase III Results of the GENUINE Study in CLL

Name: Dr. Sharman on the Phase III Results of the GENUINE Study in CLL
Uploaded: 2017-06-05T04:09:46.000Z
Description: Jeff Sharman, MD, medical director, Hematology Research, The US Oncology Network, discusses the phase III findings of the GENUINE study, the combination of ublituximab (TG-1101) and ibrutinib (Imbruvica) for patients with previously treated high-risk chronic lymphocytic leukemia (CLL).

June 5, 2017

Jeff Sharman, MD

Video

Conference|ASCO Annual Meeting

Jeff Sharman, MD, medical director, Hematology Research, The US Oncology Network, discusses the phase III findings of the GENUINE study, the combination of ublituximab (TG-1101) and ibrutinib (Imbruvica) for patients with previously treated high-risk chronic lymphocytic leukemia (CLL).

<<<